Clofazimine
- Generic Name
- Clofazimine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4
- CAS Number
- 2030-63-9
- Unique Ingredient Identifier
- D959AE5USF
- Background
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although ...
- Indication
Clofazimine is indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. To prevent the development of drug resistance, it should be used only in combination with other antimycobacterial leprosy treatments.
- Associated Conditions
- Lepromatous Leprosy
- Associated Therapies
- -
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06649721
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Tsinghua Changgun Hospital, Beijing, Beijing, China
🇨🇳The 8th Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT05306223
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China
🇨🇳The Eighth Medical Center of PLA General Hospital, Beijing, China
Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05294146
- Locations
- 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04717908
- Locations
- 🇨🇳
The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China
🇨🇳The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China
🇨🇳Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital), Ningbo, Zhejiang, China
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 81
- Registration Number
- NCT04465695
- Locations
- 🇨🇳
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong, China
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Economic Evaluation of New MDR TB Regimens
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 73
- Registration Number
- NCT04207112
- Locations
- 🇿🇦
THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇧🇾Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
PRACTECAL-PKPD Sub Study
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 240
- Registration Number
- NCT04081077
- Locations
- 🇧🇾
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇿🇦THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.